|

Hypomethylating agent, Azacitidine or Decitabine Clinical Trials

1 actively recruiting trial

Also known as: Hypomethylating agent (HMA)

Pipeline

Phase 2: 1

Top Sponsors

  • The First Affiliated Hospital of Soochow University1

Indications

  • Acute Myeloid Leukemia1
  • Cancer1

Other1 trial

Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.